Lectures on the Ethics of T. H. Green, Mr. Herbert Spencer, and J. Martineau Henry Sidgwick

Autor: Seth, James

Publikováno v: The Philosophical Review, 1903 Sep 01. 12(5), 548-553.

Externí odkaz: https://www.jstor.org/stable/2176678

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.

Autor: MacManus MP; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia. Electronic address: Michael.Macmanus@petermac.org., Seymour JF; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia., Tsang H; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Fisher R; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia., Keane C; Frazer Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia., Sabdia MB; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Law SC; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Gunawardana J; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Nath K; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kazakoff SH; Queensland Institute of Medical Research Berghofer, Brisbane, QLD, Australia., Marques-Piubelli ML; MD Anderson Cancer Centre, Houston, TX, USA., Duenas DE; MD Anderson Cancer Centre, Houston, TX, USA., Green MR; MD Anderson Cancer Centre, Houston, TX, USA., Roos D; Royal Adelaide Hospital, Adelaide, SA, Australia., O'Brien P; Genesis Cancer Care, Newcastle, NSW, Australia., McCann A; Auckland City Hospital, Auckland, New Zealand., Tsang R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Davis S; The Alfred, Melbourne, VIC, Australia., Christie D; Genesis Cancer Care, Tugun, QLD, Australia., Cheah C; Sir Charles Gairdner Hospital, Perth, WA, Australia., Amanuel B; PathWest Laboratory Medicine WA, Australia., Cochrane T; Gold Coast University Hospital, Gold Coast, QLD, Australia., Butler J; Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia., Johnston A; Royal Hobart Hospital, Hobart, TAS, Australia., Shanavas M; Mater Adult Hospital, Brisbane, QLD, Australia., Li L; Ochsner Health, New Orleans, LA, USA., Vajdic C; UNSW Kirby Institute, Sydney, NSW, Australia., Kridel R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Shelton V; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Hershenfield S; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Baetz T; Queen's University, Kingston, Ontario, Canada., Lebrun D; Queens Cancer Research Institute, Kingston, Ontario, Canada., Johnson N; McGill Centre for Translational Research in Cancer, Quebec, Canada., Brodtkorb M; Oslo University Hospital, Norway., Ludvigsen M; Aarhus University Hospital, Aarhus, Denmark., d'Amore F; Aarhus University Hospital, Aarhus, Denmark., Thompson ER; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia., Blombery P; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia., Gandhi MK; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address: m.gandhi@uq.edu.au., Tobin JWD; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address: j.tobin@uq.edu.au.

Publikováno v: EBioMedicine [EBioMedicine] 2024 Dec; Vol. 110, pp. 105468. Date of Electronic Publication: 2024 Dec 03.

Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.

Autor: Gunawardana J; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Law SC; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Sabdia MB; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Fennell É; School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland., Hennessy A; School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland., Leahy CI; School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland., Murray PG; School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland.; Royal College of Surgeons Ireland, Adliya, Bahrain., Bednarska K; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Brosda S; Frazer Institute, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Trotman J; Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia.; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia., Berkahn L; Department of Haematology, Auckland City Hospital, Auckland, New Zealand., Zaharia A; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Birch S; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Burgess M; School of Medicine, Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute, University of Limerick, Limerick, Ireland.; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Talaulikar D; Haematology Translational Research Unit, ACT Pathology, Canberra Health Services, Canberra, Australian Capital Territory, Australia.; College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia., Lee JN; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Jude E; Austin Health, Heidelberg, Victoria, Australia., Hawkes EA; Olivia Newton John Cancer Research and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.; Transfusion Research Unit, School of Public Health and Preventative Medicine, Monash University, Melbourne, Victoria, Australia., Jain S; Anatomical Pathology Department, The Canberra Hospital, Canberra, Australian Capital Territory, Australia., Nath K; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Snell C; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Mater Pathology, Brisbane, Queensland, Australia., Swain F; Royal College of Surgeons Ireland, Adliya, Bahrain.; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Tobin JWD; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Keane C; Frazer Institute, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Princess Alexandra Hospital, Brisbane, Queensland, Australia., Shanavas M; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia., Blyth E; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Camperdown, New South Wales, Australia.; Department of Haematology, Westmead Hospital, Westmead, New South Wales, Australia.; Westmead Institute for Medical Research, The University of Sydney, Westmead, New South Wales, Australia., Steidl C; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Savage K; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Farinha P; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Boyle M; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Meissner B; British Columbia Cancer Agency, Vancouver, British Columbia, Canada., Green MR; MD Anderson Cancer Center, Houston, Texas, USA., Vega F; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Gandhi MK; Blood Cancer Research Group, Mater Research, Translational Research Institute, University of Queensland, Brisbane, Queensland, Australia.; Princess Alexandra Hospital, Brisbane, Queensland, Australia.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Nov; Vol. 99 (11), pp. 2096-2107. Date of Electronic Publication: 2024 Aug 17.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.

Autor: DiNardo CD; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Verma D; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Baran N; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Section of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Bhagat TD; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Skwarska A; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Lodi A; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Saxena K; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cai T; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Su X; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guerra VA; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Poigaialwar G; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Kuruvilla VM; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konoplev S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gordon-Mitchell S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Pradhan K; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Aluri S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Hackman GL; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Chaudhry S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Collins M; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Sweeney SR; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA.; Institute for Cell and Molecular Biology, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA., Busquets J; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Rathore AS; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA., Deng Q; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Green MR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Grant S; Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA.; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA., Demo S; Calithera Biosciences, San Francisco, CA, USA., Choudhary GS; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Sahu S; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Agarwal B; GenomeRxUS, Secane, PA, USA., Spodek M; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Thiruthuvanathan V; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Will B; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Steidl U; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA., Tippett GD; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Burger J; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kornblau S; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naqvi K; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tiziani S; Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Dell Pediatric Research Institute, Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Institute for Cell and Molecular Biology, College of Natural Sciences, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu.; Department of Oncology, Dell Medical School, Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX, USA. tiziani@utexas.edu., Verma A; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. amit.verma@einsteinmed.edu., Konopleva M; Departament of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. marina.konopleva@einsteinmed.edu.; Department of Medicine (Oncology), Blood Cancer Institute, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. marina.konopleva@einsteinmed.edu.

Publikováno v: Nature cancer [Nat Cancer] 2024 Oct; Vol. 5 (10), pp. 1515-1533. Date of Electronic Publication: 2024 Sep 19.

Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer: Abstracted from: Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate. J Clin Oncol 2004; 22:3776–83.

Autor: Yip, Desmond, Goldstein, David

Publikováno v: In Cancer Treatment Reviews 2005 31(3):236-241